IL218329A0 - A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) - Google Patents
A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)Info
- Publication number
- IL218329A0 IL218329A0 IL218329A IL21832912A IL218329A0 IL 218329 A0 IL218329 A0 IL 218329A0 IL 218329 A IL218329 A IL 218329A IL 21832912 A IL21832912 A IL 21832912A IL 218329 A0 IL218329 A0 IL 218329A0
- Authority
- IL
- Israel
- Prior art keywords
- duloxetine
- naphthyloxy
- thienyl
- crystallization
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2009-584A CZ304602B6 (cs) | 2009-09-02 | 2009-09-02 | Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) |
| PCT/CZ2010/000099 WO2011026449A1 (en) | 2009-09-02 | 2010-09-02 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218329A0 true IL218329A0 (en) | 2012-04-30 |
Family
ID=43413356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218329A IL218329A0 (en) | 2009-09-02 | 2012-02-27 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2473497A1 (cs) |
| JP (1) | JP2013503823A (cs) |
| KR (1) | KR20120047262A (cs) |
| CN (1) | CN102482254A (cs) |
| BR (1) | BR112012004862A2 (cs) |
| CZ (1) | CZ304602B6 (cs) |
| EA (1) | EA021528B1 (cs) |
| IL (1) | IL218329A0 (cs) |
| MX (1) | MX2012002621A (cs) |
| WO (1) | WO2011026449A1 (cs) |
| ZA (1) | ZA201201570B (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626735A (zh) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸度洛西汀晶型及其制备方法 |
| CN104478849A (zh) * | 2014-02-14 | 2015-04-01 | 广东东阳光药业有限公司 | 制备去甲肾上腺素再摄取双重抑制剂的方法 |
| CN106265528A (zh) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | 制备药物凝集体的方法 |
| JP2016222628A (ja) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | デュロキセチン塩酸塩の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
| US5362886A (en) | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| DE10212301A1 (de) | 2002-03-20 | 2003-10-02 | Bayer Ag | Verfahren zur Herstellung von Aryl-aminopropanolen |
| WO2004005239A1 (en) | 2002-07-09 | 2004-01-15 | Lonza Ag | PROCESS FOR THE PREPARATION OF N-MONOSUBSTITUTED β-AMINO ALCOHOLS |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| CZ297560B6 (cs) * | 2004-10-26 | 2007-02-07 | Zentiva, A. S. | Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu) |
| EP1874754A1 (en) * | 2005-03-14 | 2008-01-09 | Teva Pharmaceutical Industries Ltd | Pure duloxetine hydrochloride |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| GB0612508D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| GB0612509D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| CZ300116B6 (cs) * | 2006-12-05 | 2009-02-11 | Zentiva, A. S. | Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu |
| EP2132192B1 (en) * | 2007-03-05 | 2013-04-24 | Lupin Limited | Novel process for preparation of duloxetine hydrochloride |
-
2009
- 2009-09-02 CZ CZ2009-584A patent/CZ304602B6/cs not_active IP Right Cessation
-
2010
- 2010-09-02 WO PCT/CZ2010/000099 patent/WO2011026449A1/en active Application Filing
- 2010-09-02 MX MX2012002621A patent/MX2012002621A/es not_active Application Discontinuation
- 2010-09-02 JP JP2012527196A patent/JP2013503823A/ja active Pending
- 2010-09-02 KR KR1020127004225A patent/KR20120047262A/ko not_active Application Discontinuation
- 2010-09-02 EP EP10771629A patent/EP2473497A1/en not_active Withdrawn
- 2010-09-02 CN CN2010800392370A patent/CN102482254A/zh active Pending
- 2010-09-02 BR BR112012004862A patent/BR112012004862A2/pt not_active IP Right Cessation
- 2010-09-02 EA EA201290127A patent/EA021528B1/ru not_active IP Right Cessation
-
2012
- 2012-02-27 IL IL218329A patent/IL218329A0/en unknown
- 2012-03-01 ZA ZA2012/01570A patent/ZA201201570B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120047262A (ko) | 2012-05-11 |
| EA201290127A1 (ru) | 2013-02-28 |
| CN102482254A (zh) | 2012-05-30 |
| CZ304602B6 (cs) | 2014-07-30 |
| ZA201201570B (en) | 2013-08-28 |
| EA021528B1 (ru) | 2015-07-30 |
| EP2473497A1 (en) | 2012-07-11 |
| WO2011026449A1 (en) | 2011-03-10 |
| MX2012002621A (es) | 2012-07-03 |
| CZ2009584A3 (cs) | 2011-03-09 |
| JP2013503823A (ja) | 2013-02-04 |
| BR112012004862A2 (pt) | 2015-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL230600A (en) | Method for Preparing 4 - (Pipridine - 1 - Il) - Benzo [b] Theophane and its History | |
| IL214023A0 (en) | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride | |
| GB2460070B (en) | A method of data delivery across a network | |
| GB2461132B (en) | Method of data delivery across a network | |
| HRP20160391T1 (hr) | Kristalni oblik (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidroklorida monohidrata | |
| PL2379299T3 (pl) | Sposób wypełniania osłony | |
| IL183245A0 (en) | Process for preparing phamaceutically acceptable salts of duloxetine and intermediates thereof | |
| EP1976844A4 (en) | IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE | |
| EP2237574A4 (en) | METHOD FOR PURGING DATA FROM THE BUFFER MEMORY OF A SERVING GATEWAY | |
| ZA201203115B (en) | Method for producing a mouthpiece cover of a cigaratte | |
| GB0810503D0 (en) | Method of data delivery across a network | |
| IL218329A0 (en) | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) | |
| EP2380563A4 (en) | ENTERIC FORMULATION OF DULOXETINE, ITS HEART, AND PREPARATION METHOD THEREOF | |
| EP2328815A4 (en) | IMAGE CAPTURE DEVICE | |
| EP2465293A4 (en) | TRANSFER METHOD FOR MINIMIZING DATA TREATED TO A TARGET NODE | |
| IL191921A0 (en) | A novel process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate | |
| GB0612508D0 (en) | Crystalline duloxetine hydrochloride | |
| GB0700830D0 (en) | Crystalline duloxetine hydrochloride | |
| GB0612506D0 (en) | Crystalline duloxetine hydrochloride | |
| EP2016066A4 (en) | PROCESS FOR PREPARING DULOXETINE | |
| GB0815458D0 (en) | Method of transferring timing information over packet network | |
| WO2008093360A3 (en) | A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride | |
| EP1999675A4 (en) | METHOD FOR MAKING A HORN SKIN BAG | |
| IL193402A0 (en) | Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | |
| BRPI0922856A2 (pt) | processo para preparar (6s)-(-)-5,6,7,8-tetra-hidro-6-[propil-(2-tienil)etil] amino-1-naftol (rotigotina) |